EUNICE ONTITA: Open Payments
NPI 1104326784 · GARLAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,969 in 310 payments from 15 companies in 2025. Trend: 2023 $3,365 · 2024 $3,954 · 2025 $4,969
Food & beverage: $4,870Education: $99
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 39 | $740 |
| ABBVIE INC. | 57 | $675 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 39 | $499 |
| Otsuka America Pharmaceutical, Inc. | 22 | $466 |
| Teva Pharmaceuticals USA, Inc. | 23 | $381 |
| Axsome Therapeutics, Inc. | 18 | $380 |
| Neurocrine BioSciences, Inc. | 20 | $369 |
| Alkermes, Inc. | 21 | $308 |
| E.R. Squibb & Sons, L.L.C. | 21 | $288 |
| Lundbeck LLC | 15 | $248 |
Products named: FANAPT, VRAYLAR, CAPLYTA, REXULTI, Auvelity, INGREZZA, ARISTADA, COBENFY.
Industry payments across TX — which companies pay providers there.
